key: cord-0808461-uxduueho
authors: Wadei, Hani M.; Gonwa, Thomas A.; Leoni, Juan C.; Shah, Sadia Z.; Aslam, Nabeel; Speicher, Leigh L.
title: COVID‐19 infection in solid organ transplant recipients after SARS‐CoV‐2 vaccination
date: 2021-05-18
journal: Am J Transplant
DOI: 10.1111/ajt.16618
sha: 64c9aaa1c182c221805f3989b816f960af738a1e
doc_id: 808461
cord_uid: uxduueho

The prevalence and mortality of COVID-19 are higher in solid organ transplant recipients (SOTs) compared to the general population (1-3). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by the FDA, both are 95% efficient in preventing COVID-19 in the general population. The efficacy of these vaccines in SOTs remains to be unknown as immunocompromised patients have been excluded from the vaccine studies.

Abbreviations: CP, convalescent plasma; DC, discharged; Dexa, dexamethasone; L, left; MAB 1, bamlanivimab; MAB2, casirivimab/imdevimab; N/V, nausea and vomiting; ND, not done; R, right; RA, room air; Remd, remdesivir; SOB, shortness of breath.

Predictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: a systematic review of a globally representative sample

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Covid-19 and kidney transplantation

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

SARS-CoV-2 infection after vaccination in health care workers in California